Checkpoint Therapeutics’ (CKPT) “Neutral” Rating Reaffirmed at HC Wainwright

HC Wainwright restated their neutral rating on shares of Checkpoint Therapeutics (NASDAQ:CKPT) in a research note issued to investors on Tuesday morning,Benzinga reports. They currently have a $4.10 target price on the stock.

CKPT has been the topic of a number of other research reports. D. Boral Capital restated a “buy” rating and issued a $4.80 target price (down previously from $9.00) on shares of Checkpoint Therapeutics in a research note on Monday. Lake Street Capital restated a “hold” rating and issued a $4.10 target price (down previously from $7.00) on shares of Checkpoint Therapeutics in a research note on Monday.

Checkpoint Therapeutics Stock Up 0.5 %

Shares of NASDAQ CKPT opened at $4.00 on Tuesday. Checkpoint Therapeutics has a twelve month low of $1.38 and a twelve month high of $4.50. The stock’s 50 day moving average price is $3.13 and its 200-day moving average price is $3.10. The company has a market capitalization of $195.33 million, a PE ratio of -2.17 and a beta of 1.41.

Insider Buying and Selling

In related news, CEO James F. Oliviero III sold 10,331 shares of Checkpoint Therapeutics stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $3.15, for a total value of $32,542.65. Following the sale, the chief executive officer now owns 3,775,019 shares of the company’s stock, valued at approximately $11,891,309.85. The trade was a 0.27 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO William Garrett Gray sold 268,432 shares of the business’s stock in a transaction on Wednesday, December 18th. The shares were sold at an average price of $4.01, for a total transaction of $1,076,412.32. Following the sale, the chief financial officer now directly owns 1,032,754 shares in the company, valued at $4,141,343.54. The trade was a 20.63 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 582,336 shares of company stock valued at $2,156,801. 2.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On Checkpoint Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC raised its holdings in Checkpoint Therapeutics by 4.1% during the 4th quarter. Geode Capital Management LLC now owns 445,111 shares of the company’s stock valued at $1,425,000 after acquiring an additional 17,460 shares during the period. 683 Capital Management LLC bought a new stake in Checkpoint Therapeutics during the 4th quarter valued at $522,000. HB Wealth Management LLC raised its holdings in Checkpoint Therapeutics by 96.9% during the 4th quarter. HB Wealth Management LLC now owns 153,560 shares of the company’s stock valued at $513,000 after acquiring an additional 75,560 shares during the period. PVG Asset Management Corp raised its holdings in Checkpoint Therapeutics by 9.2% during the 3rd quarter. PVG Asset Management Corp now owns 149,870 shares of the company’s stock valued at $336,000 after acquiring an additional 12,676 shares during the period. Finally, OMERS ADMINISTRATION Corp bought a new stake in Checkpoint Therapeutics during the 4th quarter valued at $374,000. Institutional investors own 22.00% of the company’s stock.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.